Importantly, the ratios of Treg cells to CD44+ CD8+ T cells in both the dLNs and tumor-infiltrating lymphocytes were remarkably reduced in the FX1-treated and combination treatment group, which suggested that the therapeutic effects of FX1 are largely mediated by Treg cells. Here, CD44 is linked to neoplasm.